Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Insulin in Spinal Cord Injury
NCT07384052Phase 1Recruiting
- Sponsor
- HealthPartners Institute
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of Generex Oral-lyn in spinal cord injury (SCI) (2 arms), sponsored by HealthPartners Institute. Primary endpoint: Number of serious adverse events (SAE) and adverse events (AE) at 3 weeks. Started Feb 2026; status: recruiting.
02
Drugs
Generex Oral-lyn
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT07384052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384052.